Dual block following tacrine and suxamethonium.
D000166:Acridines / Q000494:pharmacology / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000368:Aged; D001285:Atropine / Q000627:therapeutic use; D003472:Curare / Q000627:therapeutic use; D004491:Edrophonium / Q000627:therapeutic use; D004558:Electric Stimulation; D004594:Electrophysiology; D005260:Female; D005703:Gallamine Triethiodide / Q000627:therapeutic use; D006801:Humans; D007977:Levallorphan / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009132:Muscles / Q000187:drug effects*; D009388:Neostigmine / Q000627:therapeutic use; D009469:Neuromuscular Junction / Q000187:drug effects*; D009552:Nikethamide / Q000627:therapeutic use; D013390:Succinylcholine / Q000494:pharmacology / Q000627:therapeutic use; D013746:Tetany / Q000188:drug therapy*
D000166:Acridines; D007977:Levallorphan; D009552:Nikethamide; D009388:Neostigmine; D004491:Edrophonium; D001285:Atropine; D003472:Curare; D013390:Succinylcholine; D005703:Gallamine Triethiodide